---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-22-000017"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2022-01-18T23:59:59+00:00"
generated_at: "2026-06-27T17:41:43.579564+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xeris reaffirms 2021 net sales guidance at high-end $76-80M, 55% YoY growth

## Summary
- Preliminary 2021 pro forma net sales expected at high-end of $76-80M guidance, ~55% growth vs 2020.
- Year-end 2021 preliminary cash, equivalents, and investments ~$102M.
- Over 20M Medicaid lives in IL, TN, PA, OH, CA now have unrestricted access to Gvoke as of Jan 1, 2022.
- Third product Recorlev approved; launch in near term; additional $30M raised early 2022.
- Full Q4 and FY 2021 results and 2022 guidance expected in March 2022.

## SEC filing metadata
- accession: 0001867096-22-000017
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2022-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000017/0001867096-22-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000017/xers-20220118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-22-000017
- JSON: https://secwatch.observer/filing/0001867096-22-000017.json
- Plain text: https://secwatch.observer/filing/0001867096-22-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.